Strategies to improve outcome of Limited Stage SCLC

Dr. Ivana Sullivan
Hospital de la Santa Creu i Sant Pau, Barcelona

New hopes in relapse/progression SCLC

Dr. Noemí Reguart
Hospital Clínic Barcelona

Reassessing multidisciplinary approaches in Mesothelioma

Dr. Ernest Nadal
ICO, Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona

Discussion

Duration of therapy and retreatment opportunities

Dr. Rosario García-Campelo
Hospitalario Univ. de A Coruña

Critical evaluation of potential predictive factors

Dr. Rafael López
Hospital Clínico Univ. de Valladolid

Overcoming resistance to immunotherapy

Dr. Joaquim Bosch
ICO, Hospital Univ. Dr. Josep Trueta, Girona

Discussion

Dual use of malignant effusions for genotyping and drug screening in personalized therapy of lung cancer patients

Second neoplasms in non-small cell lung carcinoma according to sex and tobacco

Detection and categorization of new mutations ALK in massive sequencing in patients with non-small cell lung cancer

Unveiling the immune key: HLA-I and CD73 as a catalyst for long-term triumph in non-small cell lung cancer patients undergoing immunotherapy

Microbiome analysis predicts neoadjuvant treatment outcomes with chemo-immunotherapy in resectable NSCLC

Neutrophile-lymphocyte ratio as a prognostic marker of inmmunotherapy outcome in advanced NSCLC

Lost in translation. Barriers from research to clinic

Dr. Luis Paz Ares
Hospital Univ. 12 de Octubre, Madrid

EGFR beyond osimertinib

Dr. Enric Carcereny
ICO, Hospital Univ. Germans Trias i Pujol, Badalona, Barcelona

How to treat uncommon EGFR mutations

Dr. Xabier Mielgo
Hospital Univ. Fundación Alcorcón, Madrid

HER2 role in lung cancer

Dr. Virginia Calvo
Hospital Univ. Puerta de Hierro, Majadahonda, Madrid

Discussion

Next challenges. Resistance mechanisms

Dr. Ana Laura Ortega
Hospital Univ. de Jaén

ALK. The optimal sequence of treatments

Dr. Luís León-Mateos
Hospital Clínico Univ. de Santiago de Compostela

KRAS. Is it a real target?

Dr. Óscar Juan-Vidal
Hospital Univ. y Politécnico La Fe, Valencia

MET double role as oncogenic target and resistance mechanism

Dr. Anna Estival
Hospital Univ. Insular de Gran Canaria

What other new targets are coming

Dr. Mónica Antoñanzas
Hospital Clínico San Carlos, Madrid

Discussion